AMEA
Blood draw for Guardant Reveal™ suggested to be approximately
4 weeks after surgery1
Guardant Reveal™ achieved
100% positive predictive value (PPV)
as all the patients whose samples
were positive for ctDNA also had
recurrence of the cancer.1
Important note: Guardant Reveal was developed as a Laboratory Developed Test (LDT), and its performance characteristics determined, by the Guardant Health Clinical Laboratory in Redwood City, CA, USA, which is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) as qualified to perform high-complexity clinical testing. This test has not been cleared or approved by the US FDA.
In the post-surgical setting, testing for residual disease is timed to detect persistent disease and help identify patients at a high risk for recurrence.
